The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine. 1999; 341(10):709-717 269. Ponikowski P, Filippatos G, Colet JC, Willenheimer R, Dickstein K, Luscher T et al. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. European Journal of Heart Failure. 2015; 17(3):329-39 270. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. European Heart Journal. 2015; 36(11):657-68 Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 271. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016; 37(27):2129-200 272. Postmus D, Abdul Pari AA, Jaarsma T, Luttik ML, van Veldhuisen DJ, Hillege HL et al. A trial- based economic evaluation of 2 nurse-led disease management programs in heart failure. American Heart Journal. 2011; 162(6):1096-1104 273. Pufulete M, Maishman R, Dabner L, Mohiuddin S, Hollingworth W, Rogers CA et al. Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model. Health Technology Assessment. 2017; 274. Pulignano G, Del Sindaco D, Di Lenarda A, Tarantini L, Cioffi G, Gregori D et al. 